ESMO 2023 – low-dose volrustomig hints at a therapeutic window
But efficacy still needs to go up, as several groups try to combine PD-1 and CTLA-4 using differing approaches.
ESMO 2023 – Perla gives Jemperli combos more backing
The numerical survival benefit versus Keytruda underperform’s Merck’s phase 3 study, but there’s a possible reason for that.
Novartis goes 0 for 2 in PD-1 blockade
BeiGene regains rights to tislelizumab as another oncology asset blows up for Novartis.
